Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (143)	3/10/2004 3:24:07 PM
From: keokalani'nui	Respond to of 295

An upgrade shortly before a hugely important pivotal trial, arguing you'll be OK if it fails because of the brain cancer market? I'm sure I would not have the guts to make that call supported by that rationale. I don't know the first thing about osip, BTW, which doesn't say much for me.

To: tuck who wrote (143)	3/10/2004 6:29:48 PM
From: Miljenko Zuanic	Respond to of 295

As WE indicated recommending and upgrading OSIP target price, even IF NSCLC failed is suspicious. They didn't say when to buy? Before or after news. Maybe they have inside info that trial results WILL be positive, so they are confident in stock price target. Last time they recommended shorting DNA, few hrs. before Avastin news surface. Personally, and for several reasons (which I WILL NOT elaborate, regardless who ask further questions) I am short OSIP (@40). Regardless of the NSCLC outcome. Miljenko <<Also, wondering how binary the TOP data for NPSP's PREOS will be.>> Binary event is one or two day trading window. I do not do that. No opinion.